News
Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...
1h
Health and Me on MSNWegovy Approved For MASH Treatment With Fibrosis But No Cirrhosis
FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...
Gastroenterologist Dr Salhab warns that liver cirrhosis can lead to overt hepatic encephalopathy, impacting brain function and overall well-being.
9h
Medpage Today on MSNSemaglutide Gets FDA Greenlight for MASH
The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...
Liver failure syndromes are characterized by a dysregulated immune response leading to immune paralysis. Adrenomedullin (ADM) ...
18h
Health and Me on MSNGastroenterologist Warns: Cirrhosis Is Not Just About the Liver; It Can Impact Your Brain
When the liver is badly scarred by cirrhosis, the consequences are not just digestive. It can creep up and affect your brain ...
Prosecutors charged Blair Hamilton Hayes, 61 with causing the death of 47-year-old Emma Jean Teague this March ...
Novo Nordisk’s stock popped Monday after it announced a cash discount for uninsured Ozempic users and gained FDA approval for ...
The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...
The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...
A man accused of leaving a “fragile” woman in an unheated camper during the winter is at fault in her cold-related death, ...
With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results